Fusilev is owned by Acrotech.
Fusilev contains Levoleucovorin Calcium.
Fusilev has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Fusilev are:
Fusilev was authorised for market use on 07 March, 2008.
Fusilev is available in solution;intravenous, powder;intravenous dosage forms.
The generics of Fusilev are possible to be released after 07 March, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6500829||ACROTECH||Substantially pure diastereoisomers of tetrahydrofolate derivatives|| |
(1 year, 15 days ago)
Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 07 March, 2008
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic